Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telix Pharmaceuticals Ltd. ( (AU:TLX) ) has shared an update.
Telix Pharmaceuticals Ltd. has announced the acquisition of next-generation therapeutic assets and a novel biologics technology platform. This strategic move is expected to enhance the company’s product pipeline and strengthen its position in the radiopharmaceuticals market, potentially impacting its operations and market competitiveness.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Ltd. operates within the pharmaceutical industry, focusing on the development of diagnostic and therapeutic radiopharmaceuticals. Its lead imaging product, Illuccix®, is a gallium-68-based injection approved for use by regulatory bodies in the United States, Australia, and Canada.
YTD Price Performance: 2.52%
Average Trading Volume: 3,654
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $4.93B
For an in-depth examination of TLX stock, go to TipRanks’ Stock Analysis page.